Supply of NIV Drugs to Directorate of Procurement (Navy), Islamabad

The Directorate of Procurement (Navy), Islamabad invites sealed bids from original manufacturers, authorized distributors, and suppliers registered with income tax and sales tax departments for the supply of NIV Drugs as per the detailed schedule in DP-2 form. This procurement covers 39 specific drug items including Miconazole Nitrate 2% W/W, Sucralfate Syrup, Famotidine tablets and syrup, Lansoprazole, Esomeprazole, Domperidone Maleate, Mebeverine HCL, Drotaverine, Sodium Biphosphate Enema, Almond Oil, Alendronate, Mecobalamin, Ursodeoxycholic Acid, L-Ornithine L-Aspartate, Carvedilol, Bisoprolol, Diltiazem, Amlodipine, Ramipril, Losartan, Valsartan, Candesartan, Spironolactone + Frusemide, Diosmin + Hesperidin, Dobutamin, Ezetimibe, and Cetirizine Syrup among others. The technical scope requires compliance with detailed specifications, shelf life requirements, packaging standards, and delivery schedules from 1st July 2027 to 30th June 2028. Inspection will be conducted by Pakistan Navy Medical Stores Depot at Karachi and Islamabad. Eligibility criteria include valid DGDP registration or willingness to register, FBR Active Taxpayers List status, PEC category compliance, and submission of earnest money as per tender conditions. The bidding process follows a Single Stage Two Envelope procedure with separate technical and commercial offers. Earnest money must be submitted in a separate sealed envelope. Bids must be delivered to the Directorate of Procurement (Navy), Bahria Gate, Near SNID Centre, Naval Residential Complex, Sector E-8, Islamabad by 04 November 2026 at 1030 hours. Technical offers will be opened first at 1100 hours the same day. A practical tip for bidders is to ensure all technical documents, including DGDP registration, GMP certificates, and compliance forms, are complete and properly flagged to avoid rejection. Also, strictly adhere to the packaging and shelf life requirements to pass inspection and avoid penalties. This tender offers a significant opportunity for pharmaceutical suppliers to engage with a reputable government agency under clear and transparent procurement rules.